

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Case No. 02-134-D)**

<b>In application of:</b>	)	
<b>Lavie <i>et al.</i></b>	)	
	)	<b>Before the Examiner:</b>
	)	
<b>Serial No. To Be Assigned</b>	)	
	)	<b>Group Art Unit:</b>
<b>Filed: March 1, 2004</b>	)	
	)	
<b>For: Use of Specifically Engineered</b>	)	
<b>Enzymes to Enhance the Efficacy</b>	)	
<b>of Prodrugs</b>	)	

Commissioner for Patents  
Alexandria, VA 22313-1450

Sir/Madam:


**STATEMENT UNDER 37 CFR 1.821**

The undersigned representative hereby declares that the content of the paper and computer readable copies of the Sequence Listing, submitted in the above-identified application in accordance with 37 CFR 1.821 are identical in content. The 3.5" diskette contains an IBM compatible dos-text file of the sequence listing named "02-134-D.ST25.txt."

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Date: March 1, 2004

By:

  
Jason J. Derry, Ph.D.  
Reg. No. 50,692